Amy Otto

Amy Otto currently serves as the Head of Oncology Program Strategy Leadership and Vice President of Program Strategy Leader for the Trodelvy Program at Gilead Sciences. Prior to this role, Amy held the position of Executive Director and Global Product Team Leader at Seagen, where responsibilities included driving the product strategy for PADCEV and coaching teams on lifecycle plan development. With extensive experience at Amgen, Amy developed strategic frameworks and led project management initiatives that supported the successful approval of over ten products. Amy began a career in science at Merck, focusing on antibody assay development for clinical trials. Education includes an MBA from Pepperdine Graziadio Business School and participation in the Amgen Women's Leadership Institute at UCLA.